Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 774 results for "Victoza"

Once-Weekly Dulaglutide Is Noninferior to Daily Liraglutide

The investigational once-weekly dulaglutide (Eli Lilly) is noninferior to once-daily liraglutide ( Victoza , Novo Nordisk), providing similar glycated hemoglobin (HbA 1c ) reductions, in adults with type 2 diabetes poorly controlled with metformin, ... American Journal of Public Health, 4 days ago

27 images for Victoza

Mercola, 2 weeks ago
RTTNews.com, 1 month ago
MedPage Today, 1 month ago
Diabetes.co.uk, 1 month ago
Diabetes.co.uk, 1 month ago
Drug Discovery and Development, 1 month ago
FOXNews.com, 1 month ago
Diabetes.co.uk, 1 month ago
New York Daily News, 1 month ago
TopNews New Zealand, 1 month ago

Novo Nordisk Reveals Positive Data on Victoza 3 mg

Novo Nordisk A/S 's ( NVO ) Victoza (liraglutide 3 mg) showed statistically significant results in the randomized, placebo-controlled, double-blind, phase IIIa SCALE Diabetes study (n=846) for chronic weight management. Victoza (once-daily), ...
 Yahoo! Finance1 month ago Novo Nordisk's Victoza 3 mg Positive in Phase III  Yahoo! Finance1 month ago
[x]  
RTTNews.com

Diabetes Drug Victoza May Also Help With Weight Loss, Study Says

Victoza, a diabetes drug developed by Novo Nordisk, may help with appetite suppression and weight loss, according to research conducted by the pharm maker. The study, presented at the American Diabetes Association meeting in San Francisco, surveyed ...
 RTTNews.com1 month ago Novo Nordisk Type 2 Diabetes Drug Increases Weight Loss  Pharmaceutical Manufacturing Magazine1 month ago Late-stage trial: Victoza works for weight loss  MedCity News1 month ago Diabetes drug appears effective for weight loss, study shows  FOXNews.com1 month ago
[x]  

Human medicines European public assessment report (EPAR): Victoza, liraglutide, Revision: 9, Authorised

This is a summary of the European public assessment report (EPAR) for Victoza. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ...
 European Medicines Agency1 month ago GLP-1 Receptor Agonists in T2DM -- Guidelines vs Practice  General Medicine eJournal3 weeks ago
TopNews New Zealand

Novo Nordisk's Thomsen Says IDegLira Data Unprecedented

Novo Nordisk A/S (NOVOB)'s combination of a new insulin with its established Victoza therapy lowered blood-sugar to unprecedented levels and should be an important diabetes treatment once approved, Chief Science Officer Mads Krogsgaard Thomsen said.
 BusinessWeek1 month ago IDegLira data unprecedented: Thomsen  TopNews New Zealand1 month ago
MedCity News

EU agency recommends approval of Novo's insulin + type 2 diabetes treatment combo

LONDON (Reuters) - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company. The European Medicines Agency ...
 MedCity News3 days ago Novo Nordisk gains CHMP backing for Tresiba, Victoza combination therapy for diabetes  FirstWord Pharma3 days ago UPDATE 1-Novo wins EU recommendation for two-in-one diabetes drug  Reuters3 days ago Novo wins EU recommendation for two-in-one diabetes drug  Reuters3 days ago
[x]  
MedIndia

How Diabetes Drug Liraglutide May Affect Your Heart

The diabetes drug liraglutide (Victoza; Novo Nordisk) appears to provide various heart benefits that could also be helpful for people who have diabetes. The advantages are evident when the medication is used along with exercise and diet, according ...
 EMax Health1 month ago Liraglutide Benefits Patients With Type 1 Diabetes  Medscape2 months ago Combining Liraglutide With Exercise and Diet Linked With Improved Cardiovascular Risk Factors  MedIndia1 month ago Diabetes drug Liraglutide could help lower risk factors for heart disease  Business Standard India1 month ago
[x]  

FDA Panel to Review Novo Nordisk's Victoza 3mg

Novo Nordisk ( NVO ) announced that the U.S. Food and Drug Administration (:FDA) has tentatively scheduled an Advisory Committee meeting on Sep 11, 2014, to discuss the new drug application (:NDA) submitted by the company for Victoza (liraglutide 3 ...
 Yahoo! Finance2 months ago Novo preps for FDA panel hearing on lucrative obesity use for liraglutide  FiercePharma2 months ago
The Guardian Express

Diabetes Drug May Spur Weight Loss in Obese Nondiabetics

(HealthDay News) -- The diabetes drug liraglutide (Victoza) may help obese people without the disease lose weight, a new study suggests. In this test of its effectiveness as a diet aid, people taking Victoza for over a year lost an average of 8 ...
 MedicineNet.com1 month ago Diabetes Drug & Weight Loss in Obese Nondiabetics  WebMD1 month ago Weight Loss Controversy: What's wrong with RMD?  African Entertainer1 month ago Diabetes Drug May Aid Weight Loss  The Guardian Express1 month ago
[x]  
Yahoo! News

Diabetes drug might also aid weight loss

Adults who are overweight, obese or have type 2 diabetes might be able to benefit from Danish-made Victoza, which, in its third phase of clinical trials, proved successful in weight management. Its chemical name is liraglutide and when given in 3mg ...
 Yahoo! News1 month ago Diabetes drug might also aid in weight loss, study suggests  CTV News1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less